RT Journal Article
SR Electronic
T1 Hybrid immunity from SARS-CoV-2 delta variant surge induced low to undetectable levels of neutralizing antibodies against Omicron variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.28.22269990
DO 10.1101/2022.01.28.22269990
A1 Singh, Janmejay
A1 Shaman, Heena
A1 Singh, Balwant
A1 Anantharaj, Anbalagan
A1 Pargai, Kamal
A1 Chattopadhyay, Partha
A1 Devi, Priti
A1 Maurya, Ranjeet
A1 Mishra, Pallavi
A1 Kahlon, Namrata
A1 Pandey, Rajesh
A1 Pandey, Anil Kumar
A1 Medigeshi, Guruprasad R.
YR 2022
UL http://medrxiv.org/content/early/2022/01/29/2022.01.28.22269990.abstract
AB SARS-CoV-2 variants are emerging at frequent intervals with an ability to transmit faster and evade the immune responses. Most of Indian adults have received one or two doses of vaccination and, have also been infected naturally during the first and second waves. However, whether or not this hybrid immunity is protective against the emerging variants has not been determined. We found that a single dose of ChAdOx1 nCoV-19 vaccine in individuals with prior history of COVID-19 infection induced high levels of neutralizing antibodies which associated with protection from infection. Natural infection during the delta variant surge generated neutralizing antibodies against other lineages including the omicron variant. However, most of the subjects had undetectable levels of antibodies to neutralize omicron variant in the follow-up samples collected after six months suggesting that a large majority of people in India are at risk of infection by omicron variant due to waning antibody titers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Department of Biotechnology (DBT) grants through IndCEPI Mission (BT/MB/CEPI/2016) and Translational Research Program (BT/PR30159/MED/15/188/2018). RP acknowledges funding support from IUSSTF (CLP-0033) and BMGF (CLP-0036). The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional ethics committees for human research at ESIC Hospital and Medical College (No.134/R/10/IEC/22/2021/02) and THSTI (THS 1.8.1/ (93)). Informed consent was obtained from all the participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript